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Abstract
Background: Diffuse bronchiectasis (DB) may occur in rheumatoid arthritis (RA). CFTR (cystic fibrosis transmembrane
conductance regulator) mutations predispose RA patients to DB, but the prognosis of RA-associated DB (RA-DB) is unclear.
Methods:We report long-term mortality data from a nationwide family-based association study of patients with RA only, DB
only or RA-DB. We assessed mortality as a function of clinical characteristics and CF/CFTR-RD (CFTR-related disorders)
mutations in 137 subjects from 24 kindreds. Potential risk factors were investigated by Cox proportional-hazard analysis
with shared Gaussian random effects to account for within-family correlations.
Results: During a median follow-up of 11 years after inclusion, 18 patients died, mostly from cardiorespiratory causes.
Survival was significantly lower for RA-DB patients than for unaffected relatives and for patients with RA or DB only. RA
patients with DB had also a poorer prognosis in terms of survival after RA diagnosis (HR, 8.6; 95% CI, 1.5–48.2; P= 0.014) and
from birth (HR, 9.6; 95% CI, 1.1–81.7; P= 0.039). Early onset of DB (HR, 15.4; 95% CI, 2.1–113.2; P= 0.007) and CF/CFTR-RD
mutation (HR, 7.2; 95% CI, 1.4–37.1; P= 0.018) were associated with poorer survival in patients with RA-DB. Thus, CF/CFTR-RD
mutations in RA patients with early-onset DB defined a subgroup of high-risk patients with higher mortality rates (log-rank
test P= 1.2861025).
Conclusion: DB is associated with poorer survival in patients with RA. Early-onset DB and CFTR mutations are two markers
that identify RA patients at a high risk of death, for whom future therapeutic interventions should be designed and
evaluated.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease, of
unknown origin, that affects 0.5–1.0% of the adult population
worldwide [1]. It primarily involves the joints, but extra-articular
manifestations, such as lung involvement, have been observed and
may increase the burden of this frequently disabling disease. Most
studies in RA patients have reported higher mortality rates than
for the general population and have shown that extra-articular
manifestations contribute to premature death [2,3].
There is a well-established association between RA and diffuse
bronchiectasis (DB). In prospective blind studies based on high-
resolution computed tomography (HRCT) in patients with RA,
the prevalence of diffuse bronchiectasis has been reported to range
from 5.6% to 30% [4–9]. Conversely, RA is found in 2.7% to
5.2% of patients with DB referred to respiratory medicine
departments for investigation [10,11]. In cases of symptomatic
DB in RA patients, respiratory symptoms precede the onset of RA
in more than 90% of cases, with a mean interval of more than 30
years between the onset of the two diseases (early-onset, mostly
childhood DB) [10,12–16]. In less than 10% of patients,
respiratory symptoms of DB occur concomitantly with the onset
of arthritis (late-onset and adulthood DB) [17]. The prognosis of
these two subtypes of DB in RA patients remains unclear. Recent
data have suggested that the lung may be an early site of
autoimmune-related injury in RA patients and a potential site
involved in RA-related autoimmunity [18,19]. Further analyses of
the link between RA and DB are, therefore, required.
Cystic fibrosis transmembrane conductance regulator (CFTR)
gene mutations have been identified as the cause of cystic fibrosis
(CF) [20], a disease associated with DB and impaired survival due
to respiratory insufficiency in most cases [21]. Beside CF, some DB
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may be classified as CFTR-related diseases (CFTR-RD), defined as
a clinical entity associated with CFTR dysfunction not fulfilling the
diagnostic criteria for CF [22].
We previously reported a higher prevalence of CF/CFTR-RD
mutations in patients suffering from RA-associated DB (RA-DB)
than in the general population [16]. We found a strong association
and linkage between mutations in the CF/CFTR-RD gene and
RA-DB phenotypes in a French nationwide family-based associ-
ation study [23]. CF/CFTR-RD mutations were five times more
frequent in RA-DB patients than in patients with RA only (no DB)
and cosegregated with RA-DB in the families. Furthermore, RA-
DB patients carrying at least one abnormal CFTR allele but not
fulfilling the diagnostic criteria for CF more frequently had
chronic sinusitis, a trend toward more severe pulmonary
involvement, and CFTR protein dysfunction, as demonstrated
by the lower nasal potential difference of these patients than of
patients with both RA and DB but without CF/CFTR-RD
mutations [16]. These data suggest that CF/CFTR-RD mutations
may predispose patients with RA to DB, but the vital prognosis of
the RA-DB association has not been investigated in detail, and the
influence of the clinical onset of DB and the presence of CF/
CFTR-RD mutations on survival has not been studied.
We therefore investigated long-term mortality and variables
predictive of the risk of death in a well characterized, prospectively
followed family-based cohort of patients with a diagnosis of RA
only, DB only, or RA-DB.
Methods
The study protocol was reviewed and approved by the
institutional review board for clinical research of Assistance
Publique-Hoˆpitaux de Paris and the ethics committee of the
Medical Faculty of Paris Descartes University. Written informed
consent was obtained from all participants.
Study population
The study was performed in a prospectively followed family-
based cohort recruited between September 1999 and February
2002, which has been described elsewhere [23]. Briefly, for
inclusion in the study, each family had to include at least one
proband with both RA and symptomatic DB and one affected
first-degree relative with RA and/or DB. Once a family was
deemed eligible for inclusion, all affected subjects and unaffected
relatives were interviewed and blood samples were taken for
CFTR genotyping.
Interview and clinical assessment at inclusion
At inclusion, pedigree analysis was carried out and each family
member underwent face-to-face semi-structured interviews and
clinical assessment. Given the known association of RA and DB
and the possibility of asymptomatic or paucisymptomatic DB, all
RA patients underwent HRCT of the lungs. An HRCT scan of
the lungs was also conducted for other participants presenting
respiratory symptoms. All cases of DB were confirmed by two
independent observers finding evidence of diffuse (more than one
lobe) bronchiectasis on HRCT scan, without knowledge of the
CFTR mutational status of the individual concerned. In patients
with both RA and DB, DB was defined as early-onset DB if
respiratory symptoms preceded RA by more than 10 years (mostly
childhood DB) and as late-onset DB for patients whose respiratory
symptoms occurred at the same time or less than 10 years before
RA onset (adulthood DB). Participants were classified into four
categories: RA-DB, RA without DB (RA only), DB only and
unaffected.
CFTR genotyping
We checked the entire coding region and exon/intron junctions
of CFTR for CF/CFTR-RD mutations, which were subsequently
confirmed by direct DNA sequencing, as previously described
[23]. Nucleotide substitutions were classified according to their
known or predicted functional consequences [23] and groups of
mutations were considered collectively in the analyses.
Survival
The primary outcome measure was survival between November
2011 and December 2012. Data were censored on December 31st,
2012. Vital status was recorded in this family-based cohort, with a
new questionnaire that was sent to each participant and a follow-
up interview carried out for all families. Information about the
cause of death was collected retrospectively from a family
questionnaire and medical reports. Survival from inclusion was
determined for all participants and survival from birth and from
RA diagnosis was also analyzed.
Statistical analysis
The characteristics of the patients (sex ratio, age at inclusion,
age at diagnosis, median follow-up) were compared between the
groups in chi-squared tests, Fisher’s exact tests or Kruskal-Wallis
tests, as appropriate.
Survival analysis was performed with the R package ‘‘survival’’
[24]. Kaplan-Meier survival curves were plotted with the
‘‘plot.survfit’’ function and the log-rank test, implemented in the
‘‘survdiff’’ function, was used to compare survival between groups.
We adjusted for the effect of covariates and estimated hazard
ratios (HR) while accounting for family correlations, by fitting Cox
models with Gaussian random effects models to the data with the
R package ‘‘coxme’’ [25]. Each individual was assumed to have a
random genetic risk, but risks were correlated between individuals
according to the strength of their pedigree relationship, as assessed
by their kinship coefficient. We report HR and 95% confidence
intervals (95% CI) and the P-value of the z test.
We compared survival from inclusion, adjusted for age at
inclusion, between the individuals included in the study, as a
function of their disease status. We then focused on RA patients
and compared their survival from birth and from RA diagnosis as
a function of whether or not they had DB (comparison of RA-DB
with RA only). Finally, we focused on patients with both RA and
DB and investigated the factors potentially influencing their
survival from birth or from RA diagnosis.
All analyses were conducted with R version 2.15.1 [26].
Results
Patients’ characteristics
The family-based cohort comprised 137 subjects from 24
kindreds, including 30 patients with RA-DB, 25 patients with RA
only and eight patients with DB only; the remaining participants
constituted the unaffected relatives.
The main demographic features of the participants enrolled in
the family-based cohort are shown in Table 1. The median follow-
up time after inclusion was 10, 11, 11, and 12 years for patients
with RA-DB, RA only, DB only, and unaffected relatives,
respectively.
Survival in different groups of individuals
At the time of analysis, vital status was known for all subjects.
Eighteen patients and 11 unaffected relatives from the study
cohort had died (Table 1). In patients with RA-DB, the reported
cause of death was identified in 12 of the 14 patients who died, and
Survival in RA-Associated Bronchiectasis
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cardiorespiratory disease was the principal cause of death reported
for eight of these patients.
There were more deaths after inclusion among the patients with
RA-DB than among the other groups (RA only, DB only,
unaffected relatives) (Table 1), even after adjustment for age at
inclusion (Fig. 1A). RA-DB patients tended to be older at inclusion
than patients with RA only or DB only (Table 1). We therefore
also compared survival from birth between the different groups
(Fig. S1A). For patients with RA or DB only, survival after
inclusion or since birth was not significantly different from the
survival of unaffected relatives (log-rank test P=0.71 and
P=0.21, respectively). By contrast, survival was a mean of 8.6
years shorter for RA-DB patients than for unaffected relatives (log-
rank test P=6.261025) (Fig. 1A and Fig. S1A). In mixed effect
Cox models, with unaffected relatives as the reference group, the
HR for death was significant only for patients with RA-DB,
whether we took inclusion in the study (HR, 7.61; 95% CI, 2.68–
21.59; z-test P=0.00014) (Fig. 1B) or birth as the starting points
(Fig. S1B).
Survival in rheumatoid arthritis patients with and without
bronchiectasis
The survival of RA-DB patients after RA diagnosis was
significantly lower than that of patients with RA only, even after
adjusting for age of diagnosis (Fig. 2). Kaplan-Meier estimates of
the probability of survival 15 years after RA diagnosis were 82.8%
(95% CI, 70.2% to 97.8%) for RA-DB patients and 95.2% (95%
CI, 86.6% to 100%) for patients with RA only (P=0.022). In the
mixed effect Cox model adjusted for age at RA diagnosis, the HR
for death associated with the presence of DB was 8.6 (95% CI, 1.5
to 48.2; z-test P = 0.014) (Fig. 2B). We obtained similar results if
we considered survival from birth, with a HR for death associated
with the presence of DB of 9.6 (95% CI, 1.1 to 81.7; z-test
P=0.039).
Factors influencing survival in patients with both
rheumatoid arthritis and bronchiectasis
We found that 18 of the 30 patients with RA-DB (60%) had
early-onset DB, whereas the other 12 patients with RA-DB (40%)
had late-onset DB. Individuals with early-onset DB tended to be
diagnosed with RA at younger ages than those with late-onset DB.
We therefore studied survival from birth in RA-DB patients.
In univariate analyses of survival from birth, early-onset DB,
CF/CFTR-RD mutations and being male were associated with
poorer survival (Table 2).
Multivariate analysis of survival from birth showed that, in
patients with RA-DB, an early onset of DB (HR, 15.4; 95% CI,
2.1 to 113.2; P=0.0072) and CF/CFTR-RD mutations (HR, 7.2;
95% CI, 1.4 to 37.1; P=0.018) were the two major determinants
associated with poorer survival (Table 2). Eight of the 14 RA-DB
Table 1. Characteristics and outcome of the 137 participants in the family-based cohort study.
Characteristics RA-DB RA only DB only Unaffected relatives P value
(N=30) (N=25) (N=8) (N=74)
Sex ratio (F/M) 25/5 17/8 5/3 37/37 0.011a
Median (mean) age at RA onset 2 yr 45 (45.1) 39 (42.0) - - 0.35b
Median (mean) age at inclusion 2 yr 64.0 (60.1) 51.0 (51.1) 45.5 (50.1) 52.0 (54.7) 0.08b
Symptoms at inclusion
Dyspnea 2 no. (%) 24 (80%) 7 (86%) 1a
Cough and sputum 2 no. (%) 24 (80%) 7 (86%) 1a
.1 respiratory infection/year 2 no. (%) 19 (63%) 6 (71%) 0.69a
Sinus involvement 2 no. (%) 14 (47%) 5 (63)% 0.69a
Hemoptysis 2 no. (%) 7 (23%) 3 (38%) 0.41a
Subjects with at least one CFTR mutation
2 no. (%)
18 (60%) 5 (20%) 6 (75%) 16 (22%) 5.561025 a
Age when last seen 2 yr 0.15b
Median 70.5 62 56 65.5
Mean+SD 69.57+9.74 62.80+12.70 61.00+17.74 67.07+14.45
Median (mean) follow-up time 2 yr 10 (9.5) 11 (11.7) 11 (10.9) 12 (12.4) 0.06b
Deaths 2 no. (%) 14 (46.7%) 2 (8.0%) 2 (25.0%) 11 (14.9%) 0.0015a
Cause of death – no.
cardiorespiratory 8 1 1
others 4* 1{ 1` 5¥
unknown 2 1 5
RA: rheumatoid arthritis; DB: diffuse bronchiectasis. CFTR: cystic fibrosis transmembrane conductance regulator gene.
Plus-minus values are means+SD.
a
P-values of Fisher exact tests.
b
P-values of Kruskal-Wallis tests.
* Causes of death included CVA, Hodgkin lymphoma, cancer, and refractory RA, in one patient each.
{ Cause of death was CVA.
` Cause of death was cancer.
¥ Causes of death included cancer in 4 patients and degenerative neurological disease in one patient.
doi:10.1371/journal.pone.0110066.t001
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patients who died (57.1%) carried CF/CFTR-RD mutations and
10 (71.4%) had early-onset DB. The corresponding figures were
six of 16 (37.5%) and 8 of 16 (50%) for the surviving RA-DB
patients. The analysis classified RA patients with DB into
categories of low or high risk of death. CF/CFTR-RD mutations
in RA patients with early-onset DB defined a subgroup of high-risk
patients with higher mortality rates (log-rank test P=1.2861025).
Only RA patients with both an early onset of DB and CF/CFTR-
RD mutations were found to have significantly poorer survival and
these patients tended to develop RA at a younger age than the
other RA-DB patients. Survival from birth did not differ
significantly between patients with late-onset DB and no mutation,
patients with late-onset DB and CF/CFTR-RD mutations and
patients with early-onset DB and no mutation (log-rank test = 2.8;
2 df; P=0.251). Survival in RA-DB patients is shown according to
risk of death categories in Figure 3.
Discussion
In this prospective cohort study, DB was associated with poorer
survival in RA patients. This analysis further identified early-onset
DB and CF/CFTR-RD mutation as factors associated with a
poorer survival in RA-DB patients.
This study provides the first evidence of long-term poor survival
in patients with DB-associated RA, who were found to have an
eight times higher probability of death after RA diagnosis than
family members with RA only. Cardiorespiratory causes were the
most frequently reported causes of death in this population. These
results are similar to those of a previous controlled study, in which
the five-year probability of mortality in patients with RA-DB was
found to be five times that of a matched control group of patients
with RA alone and 2.4 times that of a group of patients with DB
alone [14]. Most of the deaths of patients with RA-DB (60%) in
this previous study were attributed to respiratory infection,
whereas the severity of RA, as assessed by HAQ, grip strength,
nodules and steroid treatment, was not significantly associated
with poorer survival [14].
In patients with RA, childhood-onset DB is much more
prevalent than late-onset DB [10,12-16]. Most (60%) of the 30
patients from our cohort with both RA and DB had early-onset
DB, beginning more than 10 years before the onset of RA. These
data are consistent with the hypothesis that the lung may be an
early target of systemic RA autoimmunity or a site at which RA-
related autoimmunity is initiated, with an initial autoimmune
response in the lung [18,19]. We found that RA-DB patients with
early-onset DB had a poorer prognosis than those with late-onset
Figure 1. Kaplan-Meier probability of survival from inclusion of the various participants in the study cohort, according to their
phenotype. Panel A. Kaplan-Meier survival curves from inclusion in the study for the various groups of individuals. Panel B. Hazard ratios (95% CI)
of death after inclusion for the various disease groups, compared with unaffected relatives as the reference group. A mixed effect Cox model was
fitted, taking inclusion as the starting point and adjusting for age at inclusion. Individual random effects were assumed to be correlated as a function
of the corresponding kinship coefficients. The variance of the random effect was 1.48. RA: rheumatoid arthritis; DB: diffuse bronchiectasis.
doi:10.1371/journal.pone.0110066.g001
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DB, and early-onset DB was identified as a major determinant of
survival in RA patients in multivariate analysis. The role of CF/
CFTR-RD mutation in the association between RA and DB has
been described before [23] and such mutations were found in 50%
of the RA-DB patients with early-onset DB and 42% of those with
late-onset DB. Not only do CF/CFTR-RD mutations predispose
RA patients to DB, they are also associated with poorer survival.
The prognostic implications of CFTR gene mutations have been
considered to date only for in patients with CF. Our results
demonstrate that RA patients with both early-onset DB and CF/
CFTR-RD mutations should be considered at high risk of death
and should receive more aggressive treatment, including smoking
cessation and physiotherapy. Most of our patients were enrolled
before the widespread use of biological agents likely to modify
Figure 2. Kaplan-Meier probability of survival after RA diagnosis in patients, as a function of the presence or absence of associated
DB. Panel A. Kaplan-Meier curves of survival after RA diagnosis, as a function of the presence or absence of associated DB. Panel B. Hazard ratios
(95% CI) for death after RA diagnosis associated with the presence of DB. A mixed effect Cox model was fitted, taking RA diagnosis as the starting
point. Individual random effects were assumed to be correlated as a function of the corresponding kinship coefficients. The variance of the random
effect was 4 1024. RA: rheumatoid arthritis; DB: diffuse bronchiectasis.
doi:10.1371/journal.pone.0110066.g002
Table 2. Analysis of survival from birth of 30 patients with both RA and DB.
Univariate analysis Multivariate analysis
P value Hazard ratio [95% CI] P value
Early-onset DB 0.009 15.4 [2.1; 113.2] 0.0072
CFTR mutations 0.073 7.2 [1.4; 37.1] 0.018
Male versus female 0.06 1.1 [0.2; 5.6] 0.92
RA: rheumatoid arthritis; DB: diffuse bronchiectasis.
Early-onset DB: respiratory symptoms preceding RA by .10 years (mostly childhood DB).
CFTR: cystic fibrosis transmembrane conductance regulator gene.
A mixed effect Cox model was used, with shared random effects, depending on the kinship coefficient of individuals.
The variance of the random effect was 461024.
doi:10.1371/journal.pone.0110066.t002
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mortality [27], but frequent pulmonary superinfections may
constitute a contraindication for such treatments in these patients
[15]. These high-risk patients should be eligible in priority in
protocols evaluating new treatment interventions such as long-
term macrolide therapy which may be beneficial in patients with
non-CF bronchiectasis [28–33] and significantly improve the signs
and symptoms of RA [34,35]. It remains unclear which patients
should receive antibiotic treatment [36], but we suggest that RA
patients with early-onset DB carrying CF/CFTR-RD mutations
should be among those treated and evaluated for long-term
azithromycin therapy.
Our study has several strengths. It is a family-based study, which
made it possible to gather long-term data for all the individuals
included. Such a family-based design limits research bias, by
providing appropriate controls and follow-up. Furthermore,
phenotypic characterization was carried out and mutational
CFTR status was determined for all individuals. We systematically
checked for DB on HRCT scans for all RA patients and for all
individuals with respiratory symptoms. These scans were assessed
by two investigators blind to the results of genetic tests.
Several limitations of this study merit further comment. The
predictors of mortality in RA include severe extra-articular
manifestations [2,37–41]. One of the limitations of this nationwide
study is the lack of information regarding other risk factors for
mortality in RA patients. These confounding factors may influence
the outcome, but the strongest predictor of mortality has been
shown to be extra-articular manifestations of the disease [2,40]
and the leading cause of death of our RA-DB patients was
cardiorespiratory complications. Sample size is another potential
limitation of this study. The limited number of patients in each
Figure 3. Kaplan-Meier probability of survival from birth of patients with both RA and DB according to risk of death categories. The
analysis classified RA patients with DB into categories of low or high risk of death. Patients with early onset of DB and CF/CFTR-related disorders
mutations were classified in the high group as compared with the other patients with both RA and DB who were classified into the low risk. RA:
rheumatoid arthritis; DB: diffuse bronchiectasis. Early-onset DB: respiratory symptoms preceding RA by .10 years (mostly childhood DB). Late-onset
DB: respiratory symptoms occurring at the same time or ,10 years before RA onset (adulthood DB). Mutations: cystic fibrosis (CF) and cystic fibrosis
transmembrane conductance regulator (CFTR)-related disorder mutations. See Patients and Methods for additional information.
doi:10.1371/journal.pone.0110066.g003
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subgroup restricts the power of this study to detect differences.
However, this series of patients with RA-DB is one of the largest
ever studied, and differences in age at onset of DB and genetic
background appear to have a significant, independent, and strong
effect on mortality. In addition, our patients were selected from
families with a history of RA or DB. It therefore remains unclear
to what extent these results can be extrapolated to patients with no
such family history. Another limitation of this study is the possible
overestimation of the survival of patients with RA and late-onset
DB with respect to that of patients with RA and early-onset DB.
Indeed, for recruitment in the study, a family had to include at
least one patient with RA and DB. Thus, if this patient had late-
onset DB, there is the possibility of a survival advantage because
he or she must have lived long enough after the onset of RA to
develop DB meeting the late-onset criterion. However, this should
not have biased the results concerning the deleterious effects of
CF/CFTR-RD mutations on survival in patients with early-onset
DB, in whom the presence of a mutation was found to lead to a
mean decrease in survival of 7.1 years on average (log rank test
= 6.3; 1 df; P=0.012).
Conclusions
In this prospective family cohort, DB in RA patients was
associated with lower overall survival. CF/CFTR-RD mutations
predispose RA patients with early-onset DB to more severe
disease, associated with a shorter lifespan. The identification of
early-onset DB and the genotyping of such patients may make it
possible to define high-risk patients for whom new treatments
should be developed and evaluated specifically.
Supporting Information
Figure S1 Kaplan-Meier probability of survival from
birth of the various participants in the study cohort as a
function of their phenotype. Panel A. Kaplan-Meier survival
curves from birth for the various groups of individuals. Panel B.
Hazard ratios (95% CI) for death since birth for the various disease
groups, compared with unaffected relatives as the reference group.
A mixed effect Cox model was fitted, taking birth as the starting
point and age as the scale. Individual random effects were assumed
to be correlated as a function of the corresponding kinship
coefficient. The variance of the random effect was 1.35. RA:
rheumatoid arthritis; DB: diffuse bronchiectasis.
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